XML 43 R27.htm IDEA: XBRL DOCUMENT v3.21.2
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Tables)
 6 Months Ended
Jun. 30, 2021
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Disposal Groups, Including Discontinued Operations [Table Text Block]
The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended June 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$132 $127 $— $— $(152)$(129)
Erbitux* Business
6 3 — — — — 
Manufacturing Operations23 10 — — — — 
Mature Brands and Other41 1 (11)9 — (1)
Total$202 $141 $(11)$9 $(152)$(130)
Six Months Ended June 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$296 $280 $— $— $(286)$(256)
Erbitux* Business
6 7 — — — — 
Manufacturing Operations23 10 — (1)— — 
Plavix* and Avapro*/Avalide*
5 7 — (12)— — 
Mature Brands and Other52 32 (11)6 (1)(32)
Total$382 $336 $(11)$(7)$(287)$(288)
(a)    Includes royalties received subsequent to the related sale of the asset or business.
Licensing and Other Arrangements [Table Text Block]
The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2021202020212020
Keytruda* royalties
$(204)$(155)$(396)$(316)
Tecentriq* royalties
(23)— (45)— 
Up-front licensing fees— — — (30)
Contingent milestone income(2)(5)(2)(46)
Amortization of deferred income(15)(15)(30)(30)
Other royalties(9)(6)(12)(11)
Total$(253)$(181)$(485)$(433)